Roche’s Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test has received clearance from the U.S. Food and Drug Administration (FDA), providing a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer’s disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline.
Developed in collaboration with Eli Lilly and Company, Elecsys pTau217 is the first and only FDA-cleared, single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.
“FDA clearance of Elecsys pTau217 marks an important milestone in Alzheimer’s disease diagnosis and underscores Roche’s continued leadership in advancing innovative solutions that can help patients get answers sooner,” said Dan Malarek, President and CEO of Roche Diagnostics North America. “As the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology, Elecsys pTau217 has the potential to transform how Alzheimer’s is assessed across primary and specialty care. This kind of innovation can help bring diagnostic evaluation closer to patients and give clinicians greater confidence in determining the right step in their care.”
The assay provides positive, intermediate and negative result categories to support assessment of the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings as part of the Alzheimer’s disease diagnostic pathway. The test is designed for use across Roche’s more than 4,500 cobas laboratory instruments in the United States, enabling broad access through existing laboratory infrastructure.
An estimated 75% of people living with dementia remain undiagnosed, and those who are diagnosed often experience years of uncertainty after symptoms first appear. Traditional approaches used to assess amyloid pathology, including positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, may be costly, invasive and difficult to access outside specialty centers.
The Elecsys pTau217 blood test helps address these barriers by providing a minimally invasive blood-based option that can be incorporated into existing clinical and laboratory workflows. The test may help clinicians assess the likelihood of amyloid pathology earlier in the disease and diagnostic pathway and identify patients who should be considered for additional evaluation or specialist referral.
"For decades, clinicians have faced significant challenges in accurately diagnosing Alzheimer's disease in its early stages. While PET imaging and cerebrospinal fluid biomarkers can confirm amyloid pathology in patients with cognitive impairment, these approaches may be costly, invasive and not readily accessible for many patients," said Jared R. Brosch, M.D., Neurologist, Indiana University Health. "Advances in blood-based biomarkers have the potential to transform the diagnostic pathway by expanding access to evaluation for Alzheimer's across a variety of care settings. As these tools become available, clinicians may be able to evaluate more patients earlier in the disease course, improving diagnostic confidence and helping patients and their families make more informed decisions at a critical time."
Evaluated in individuals 55 years and older with signs, symptoms or complaints of cognitive decline associated with Alzheimer’s disease, Elecsys pTau217 demonstrated high agreement with amyloid PET imaging, providing clinicians with a minimally invasive option for assessing amyloid pathology.
As a single-assay solution, Elecsys pTau217 simplifies laboratory implementation by using one biomarker and one set of validated clinical cutoffs to support both rule-in and rule-out assessment of amyloid pathology. Roche refers to this approach as the ‘Power of One’ - one assay, one biomarker and one set of validated clinical cutoffs designed to simplify Alzheimer’s assessment while expanding access to blood-based testing.
Elecsys pTau217 is not intended to be used as a stand-alone test. Results should be interpreted in conjunction with other diagnostic tools and clinical information. The safety and effectiveness of the assay have not been established for predicting development of dementia or other neurologic conditions or for monitoring the effect of therapeutic products.